Biblio
Export 391 results:
Author Title [ Type] Year Filters: First Letter Of Last Name is O [Clear All Filters]
“Cerebrospinal Fluid Fatty Acid-Binding Protein 3 is Related to Dementia Development in a Population-Based Sample of Older Adult Women Followed for 8 Years.”, J Alzheimers Dis, vol. 49, no. 3, pp. 733-41, 2016.
, “Cerebrospinal Fluid Markers of Alzheimer's Disease Pathology and Microglial Activation are Associated with Altered White Matter Microstructure in Asymptomatic Adults at Risk for Alzheimer's Disease.”, J Alzheimers Dis, vol. 50, no. 3, pp. 873-86, 2016.
, “Change of Amyloid-β 1-42 Toxic Conformer Ratio After Cerebrospinal Fluid Diversion Predicts Long-Term Cognitive Outcome in Patients with Idiopathic Normal Pressure Hydrocephalus.”, J Alzheimers Dis, vol. 63, no. 3, pp. 989-1002, 2018.
, “Characteristics of Cognitively Normal Mexican-Americans with Cognitive Complaints.”, J Alzheimers Dis, vol. 61, no. 4, pp. 1485-1492, 2018.
, “Characterization of Alzheimer's Disease and Mild Cognitive Impairment in Older Adults in Panama.”, J Alzheimers Dis, vol. 54, no. 3, pp. 897-901, 2016.
, “Characterization of Mild Cognitive Impairment and Dementia among Community-Dwelling Mexican Americans and Non-Hispanic Whites.”, J Alzheimers Dis, vol. 90, no. 2, pp. 905-915, 2022.
, “Chronic Cerebral Hypoperfusion Accelerates Alzheimer's Disease Pathology with Cerebrovascular Remodeling in a Novel Mouse Model.”, J Alzheimers Dis, vol. 53, no. 3, pp. 893-905, 2016.
, “Chronotropic Response and Cognitive Function in a Cohort at Risk for Alzheimer's Disease.”, J Alzheimers Dis, vol. 56, no. 1, pp. 351-359, 2017.
, “Chronotropic Response and Cognitive Function in a Cohort at Risk for Alzheimer's Disease.”, J Alzheimers Dis, vol. 56, no. 1, pp. 351-359, 2017.
, “Circulating Cell-Free Genomic DNA Is Associated with an Increased Risk of Dementia and with Change in Cognitive and Physical Function.”, J Alzheimers Dis, vol. 89, no. 4, pp. 1233-1240, 2022.
, “Circulating microRNAs as Biomarkers of Alzheimer's Disease: A Systematic Review.”, J Alzheimers Dis, vol. 49, no. 3, pp. 755-66, 2016.
, “Circulating Omega-3 and Omega-6 Fatty Acids, Cognitive Decline, and Dementia in Older Adults.”, J Alzheimers Dis, vol. 95, no. 3, pp. 965-979, 2023.
, “Clinical Benefits for Older Alzheimer's Disease Patients: Okayama Late Dementia Study (OLDS).”, J Alzheimers Dis, vol. 46, no. 3, pp. 687-93, 2015.
, “Cognitive Rehabilitation in Alzheimer's Disease: A Controlled Intervention Trial.”, J Alzheimers Dis, vol. 57, no. 4, pp. 1315-1324, 2017.
, “Cognitive Status, Gray Matter Atrophy, and Lower Orthostatic Blood Pressure in Older Adults.”, J Alzheimers Dis, vol. 57, no. 4, pp. 1239-1250, 2017.
, “Cognitive Training Interventions for Patients with Alzheimer's Disease: A Systematic Review.”, J Alzheimers Dis, vol. 56, no. 4, pp. 1349-1372, 2017.
, “Combinatorial Treatment Effects in a Cell Culture Model of Alzheimer's Disease.”, J Alzheimers Dis, vol. 55, no. 3, pp. 1155-1166, 2017.
, “Combining Select Blood-Based Biomarkers with Neuropsychological Assessment to Detect Mild Cognitive Impairment among Mexican Americans.”, J Alzheimers Dis, vol. 75, no. 3, pp. 739-750, 2020.
, “Comorbid Depression and Diabetes as a Risk for Mild Cognitive Impairment and Alzheimer's Disease in Elderly Mexican Americans.”, J Alzheimers Dis, vol. 47, no. 1, pp. 129-36, 2015.
, “Comparing Approaches to Optimize Cut-off Scores for Short Cognitive Screening Instruments in Mild Cognitive Impairment and Dementia.”, J Alzheimers Dis, vol. 57, no. 1, pp. 123-133, 2017.
, “Comparison of Different Matrices as Potential Quality Control Samples for Neurochemical Dementia Diagnostics.”, J Alzheimers Dis, vol. 52, no. 1, pp. 51-64, 2016.
, “Comparison of Steady-State Pharmacokinetics of Donepezil Transdermal Delivery System with Oral Donepezil.”, J Alzheimers Dis, vol. 90, no. 1, pp. 161-172, 2022.
, “The Complexity of Nutritional Problems in Persons with Dementia: Expanding a Theoretical Model.”, J Alzheimers Dis, vol. 96, no. 1, pp. 183-192, 2023.
, “Computational Evaluation of Azadirachta indica-Derived Bioactive Compounds as Potential Inhibitors of NLRP3 in the Treatment of Alzheimer's Disease.”, J Alzheimers Dis, vol. 94, no. s1, pp. S67-S85, 2023.
, “Computational Evaluation of Azadirachta indica-Derived Bioactive Compounds as Potential Inhibitors of NLRP3 in the Treatment of Alzheimer's Disease.”, J Alzheimers Dis, vol. 94, no. s1, pp. S67-S85, 2023.
,